From the beginning of its production, monoclonal antibodies (McAbs) directed against CD34 antigen, have been extensively explored in different hematological malignancies. Accordingly, evidence progressively accumulated that reactivity for CD34 was almost exclusive to acute leukemia blast cells while absent in chronic mature disorders. Since then, CD34 expression has been included in most panels of McAbs used to characterize the immunophenotype of immature leukemic cells as a useful marker in discriminating between mature and immature hematopoietic leukemic cells. CD34 reagents have also been used to explore the potential prognostic impact of CD34 expression as well as for its utility in identifying residual immature blast cells for minimal residual disease monitoring. However, the extended use of many different types of CD34 monoclonal antibody clones and reagents has lead to disturbing levels of variability as regards both the incidence of CD34 expression in acute leukemias and its prognostic relevance. In this paper we will review current knowledge on the clinical and biological significance of CD34 expression, first in acute myeloid leukemia (AML) and afterwards in acute lymphoblastic leukemias (ALL).

Clinical and biological significance of CD34 expression in acute leukemia.

BASSO, GIUSEPPE;
2001

Abstract

From the beginning of its production, monoclonal antibodies (McAbs) directed against CD34 antigen, have been extensively explored in different hematological malignancies. Accordingly, evidence progressively accumulated that reactivity for CD34 was almost exclusive to acute leukemia blast cells while absent in chronic mature disorders. Since then, CD34 expression has been included in most panels of McAbs used to characterize the immunophenotype of immature leukemic cells as a useful marker in discriminating between mature and immature hematopoietic leukemic cells. CD34 reagents have also been used to explore the potential prognostic impact of CD34 expression as well as for its utility in identifying residual immature blast cells for minimal residual disease monitoring. However, the extended use of many different types of CD34 monoclonal antibody clones and reagents has lead to disturbing levels of variability as regards both the incidence of CD34 expression in acute leukemias and its prognostic relevance. In this paper we will review current knowledge on the clinical and biological significance of CD34 expression, first in acute myeloid leukemia (AML) and afterwards in acute lymphoblastic leukemias (ALL).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/1475006
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 33
social impact